Companies: 10,795·Total market cap: $144.5T

Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc. Common Stock

BCAXNASDAQHealthcare● Active

$20.10

+$0.10(+0.50%)

Market Cap$1.1B

P/E Ratio—

52W High$24.25

52W Low$8.48

Avg Volume557K

Open$20.55

Beta-0.53

Net Income Financials Revenue

Bicara Therapeutics Inc. Common Stock (BCAX) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

BCAX · net income · updated Jun 8, 2026

Core profitability metrics

BCAX · net income · margin · TTM · CAGR

Net income was −$137.9M for FY2025 (fiscal year ending 2025-12-31), down 102.9% year-over-year. Net profit margin was —.

FY2025 Net Income−$137.9M▼ -102.9% YoY

Trailing 12M (TTM)−$157.3Mtrailing 4 quarters sum

Net Profit Margin——

YoY Change-102.9%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · BCAX net income history · BCAX profit margin

Annual net income data

BCAX · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$137.9M▼ 102.9%—$0

FY2024Loss−$68.0M▼ 30.8%—$0

FY2023Loss−$52.0M▼ 37.4%—$0

FY2022Loss−$37.8M——$0

Net income vs peers (Healthcare)

BCAX vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Bicara Therapeutics Inc. Common StockYOU

BCAX

−$137.9M-102.9%—

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Bicara Therapeutics Inc. Common Stock (BCAX) reported net income of −$137.9M for FY2025 (fiscal year ending 2025-12-31), down 102.9% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

Bicara Therapeutics Inc. Common Stock has not yet achieved annual profitability based on available data (4 fiscal years). The company has reported net losses across all available periods.

Bicara Therapeutics Inc. Common Stock's net profit margin was — for FY2025, based on the latest annual results.

Investors sometimes search for "Bicara Therapeutics Inc. Common Stock net worth" — the company's market capitalization is a separate figure from BCAX net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

BCAX net income · 4 questions

Bicara Therapeutics Inc. Common Stock is not currently profitable on an annual basis. The company reported a net loss of $137.9M for FY2025.

is BCAX profitabledoes BCAX make a profitBCAX profitabilityBCAX profitable company

▸ Source: FMP /income-statement · GAAP · Bicara Therapeutics Inc. Common Stock · Bicara Therapeutics Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026